| Description : |
DYRK3 (Dual-specificity Tyrosine Phosphorylation-Regulated Kinase 3) is a serine/threonine protein kinase that belongs to the DYRK (dual-specificity tyrosine-phosphorylation regulated kinase) family of kinases. It is involved in a variety of cellular processes, including regulation of the cell cycle, DNA damage response, and apoptosis. Research has suggested that DYRK3 plays a role in several diseases, including cancer, neurodegenerative diseases, and viral infections. In cancer, DYRK3 has been shown to contribute to tumor growth and survival, and inhibition of DYRK3 has been suggested as a potential cancer therapy. In neurodegenerative diseases, DYRK3 has been implicated in the regulation of neuronal survival and degeneration, and alterations in DYRK3 expression and activity have been observed in the brains of patients with Alzheimer's disease and Parkinson's disease. Additionally, inhibition of DYRK3 has been suggested as a potential therapeutic strategy for viral infections. |
| Source : |
Sf21 |
| Species : |
Human |
| Tag : |
GST,His |
| Protein length : |
Full Length |
| Form : |
0.52 mg/ml of enzyme in 50 mM Tris/HCl pH7.5, 300 mM NaCl, 0.1 mM EGTA, 0.03% Brij-35, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution. |
| Bio-activity : |
1047 U/mg, where one unit of DYRK3 activity is defined as 1 nmol phosphate incorporated into 250 μM RRRFRPASPLRGPPK per minute at 30 centigrade with a final ATP concentration of 100 μM. |
| Molecular Mass : |
94 kDa. |
| AA Sequence : |
1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID 61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV 121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK 181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSKEFM GGTARGPGRK 241 DAGPPGAGLP PQQRRLGDGV YDTFMMIDET KCPPCSNVLC NPSEPPPPRR LNMTTEQFTG 301 DHTQHFLDGG EMKVEQLFQE FGNRKSNTIQ SDGISDSEKC SPTVSQGKSS DCLNTVKSNS 361 SSKAPKVVPL TPEQALKQYK HHLTAYEKLE IINYPEIYFV GPNAKKRHGV IGGPNNGGYD 421 DADGAYIHVP RDHLAYRYEV LKIIGKGSFG QVARVYDHKL RQYVALKMVR NEKRFHRQAA 481 EEIRILEHLK KQDKTGSMNV IHMLESFTFR NHVCMAFELL SIDLYELIKK NKFQGFSVQL 541 VRKFAQSILQ SLDALHKNKI IHCDLKPENI LLKHHGRSST KVIDFGSSCF EYQKLYTYIQ 601 SRFYRAPEII LGSRYSTPID IWSFGCILAE LLTGQPLFPG EDEGDQLACM MELLGMPPPK 661 LLEQSKRAKY FINSKGIPRY CSVTTQADGR VVLVGGRSRR GKKRGPPGSK DWGTALKGCD 721 DYLFIEFLKR CLHWDPSARL TPAQALRHPW ISKSVPRPLT TIDKVSGKRV VNPASAFQGL 781 GSKLPPVVGI ANKLKANLMS ETNGSIPLCS VLPKLISGPG PGHHHHHH |
| Purity : |
Purity 85% by SDS-PAGE and Coomassie blue staining. |
| Applications : |
Drug Discovery & Development |
| Storage : |
6 months at -70 centigrade. |
| Handling Advice : |
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade. |
| Use/Stability : |
On receipt of material store at -20 centigrade. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap. |
